Thermo Fisher Scientific Inc., a leading U.S.-based medical equipment manufacturer, is reportedly close to finalizing an ...

Q3 2025 Management View Paul Bolno, President, CEO & Director, highlighted the company's "first ever demonstration of activin E reductions in a clinical trial" with WVE-007, reporting "highly ...

The shift to risk-based quality management (RBQM) in clinical trials offers market opportunities in proactive risk strategies, focusing on patient safety and data integrity. Emphasizing digital ...

Salt Lake City-based Intermountain Health is partnering with health AI company Layer Health to streamline how it manages clinical data. The multi-year collaboration, announced in a June 17 news ...

Thermo Fisher ( NYSE: TMO) is nearing a takeover of Clario in an all-cash deal that could value the clinical trial data ...

Experts at the 2025 OCT DACH conference will dive into the potential of the European region amid a shifting clinical trial ...

Disc Medicine announces positive updates on bitopertin, DISC-0974, and DISC-3405, with plans for upcoming clinical trials and data presentations. Disc Medicine, Inc. recently provided positive updates ...

Q3 2025 Management View Jon Congleton, President and CEO, shared that Mineralys received pre-NDA feedback from the FDA with "no surprises" and is moving ahead with its NDA filing for lorundrostat, ...

Thermo Fisher said on Wednesday it would buy privately held data management company Clario for up to $9.4 billion, ...

Survival models using EHR data predicted progression from NPDR or DME to PDR in type 2 diabetes patients. Key risk factors for progression included age, race, NPDR severity, and diabetic nephropathy.

ArriVent BioPharma, Inc. has announced promising findings from its clinical studies involving firmonertinib, an EGFR inhibitor promising strong anti-tumor activity against non-small cell lung cancer ...